This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the GBS/CIDP Foundation

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Grifols and CSL Behring.

DATE OF RELEASE/EXPIRATION

This activity was released on January 31, 2023 and is valid until January 31, 2024. Requests for credit must be made no later than January 31, 2024

TARGET AUDIENCE

The target audiences for the proposed HCP activity are community neurologists, neuromuscular specialists, immunologists, PCPs, hospitalists, emergency physicians, APNs, RNs, pharmacists.

STATEMENT OF NEED/PROGRAM OVERVIEW

Differentiating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) from other immune-mediated inflammatory neuropathies can be challenging for clinicians. Misdiagnoses are common and can lead to poor outcomes for patients. However, newly revised guidelines for CIDP offer an opportunity to address barriers to accurate diagnoses and appropriate treatments.

Join an expert panel of neurologists and representatives from the GBS|CIDP Foundation International to discuss disease aspects/variants, simplify accurate diagnoses, and offer evidence-based guidance on treatment options and selections. Panelists will cover the place of imaging technologies in diagnosis, recognition of CIDP based on symptoms, and testing recommendations in the 2021 guidelines. Clinicians will leave the activity better able to work with their patients to individualize treatments and incorporate emerging agents and immunoglobulin formulations as they are approved.

Do you have patients with CIDP who could benefit from education on the early symptoms and signs for this condition, along with comparisons of available treatment options? Direct your patients to NeuroCareLive.com to access the activity, “You Have CIDP…Now What?”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Integrate the 2021 European Academy of Neurology/Peripheral Nerve Society guidelines into the diagnosis and treatment of CIDP
• Summarize how new diagnostic criteria and use of imaging technology will improve the diagnosis of CIDP and its variants
• Formulate individualized treatment plans with the patient based on updated recommendations, patients’ quality of life, and measures of disability and impairment
• Summarize rationale for the need and data to date with new approaches to the treatment of CIDP, including new immunoglobulin formulations and FcRn receptor-targeted agents

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Dr. Jeffrey Allen Associate Professor University of Minnesota	Co-Owner/Founder: Argenx, Alexion, Anylym, CSL behring, Grifols, Pfizer, Jannsen, Takeda, Immunovant, Immupharma Consulting Fee: Argenx, Alexion, CSL behring, Takeda Honoraria: Argenx, Anylym, CSL behring
Dr. Lisa Butler Executive Director GBS/CIDP Foundation International	Nothing to disclose
Dr. Thomas Harbo Associate Professor, Depart of Neurology Aarhus University Hospital	Nothing to disclose

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Name of Planner or Manager	Reported Financial Relationship
Carole Drexel	Nothing to disclose
Caroline Laurendeau	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 877-394-1306 or at Support@NeuroSeriesLive.com.